

# Amarendra Pegu

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8887373/amarendra-pegu-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61  
papers

4,089  
citations

31  
h-index

63  
g-index

65  
ext. papers

5,447  
ext. citations

14.7  
avg, IF

4.75  
L-index

#	Paper	IF	Citations
61	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , <b>2020</b> , 383, 1544-1555	59.2	612
60	Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. <i>Nature</i> , <b>2014</b> , 514, 642-5	50.4	232
59	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. <i>Nature</i> , <b>2016</b> , 533, 105-109	50.4	229
58	Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. <i>Journal of Virology</i> , <b>2014</b> , 88, 12669-82	6.6	198
57	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. <i>Science Translational Medicine</i> , <b>2014</b> , 6, 243ra88	17.5	189
56	Early events in Mycobacterium tuberculosis infection in cynomolgus macaques. <i>Infection and Immunity</i> , <b>2006</b> , 74, 3790-803	3.7	189
55	Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. <i>Clinical and Experimental Immunology</i> , <b>2015</b> , 182, 289-301	6.2	177
54	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. <i>Science</i> , <b>2017</b> , 358, 85-90	33.3	176
53	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , <b>2016</b> , 90, 76-91	6.6	151
52	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> , <b>2021</b> , 373, 1372-1377	33.3	150
51	Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 664-666	59.2	137
50	Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. <i>Nature Medicine</i> , <b>2016</b> , 22, 362-8	50.5	134
49	Human herpesvirus 8 infects and replicates in primary cultures of activated B lymphocytes through DC-SIGN. <i>Journal of Virology</i> , <b>2008</b> , 82, 4793-806	6.6	108
48	Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	106
47	Use of broadly neutralizing antibodies for HIV-1 prevention. <i>Immunological Reviews</i> , <b>2017</b> , 275, 296-312	11.3	101
46	Human lymphatic endothelial cells express multiple functional TLRs. <i>Journal of Immunology</i> , <b>2008</b> , 180, 3399-405	5.3	89
45	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , <b>2015</b> , 89, 5895-903	6.6	82

44	Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. <i>Science</i> , <b>2021</b> , 373,	33.3	80
43	P13-01. Crystal structure and function of a monoclonal antibody against primate CD4 that blocks HIV/SIV infection. <i>Retrovirology</i> , <b>2009</b> , 6,	3.6	78
42	P13-07 LB. A human blocking antibody to CCR5 partially protects against lentiviral infection in non-human primates. <i>Retrovirology</i> , <b>2009</b> , 6,	3.6	78
41	Activation and lysis of human CD4 cells latently infected with HIV-1. <i>Nature Communications</i> , <b>2015</b> , 6, 8447	17.4	73
40	Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization. <i>Journal of Virology</i> , <b>2015</b> , 89, 12501-12	6.6	67
39	Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. <i>Science Translational Medicine</i> , <b>2017</b> , 9,	17.5	65
38	Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. <i>Journal of Virology</i> , <b>2016</b> , 90, 1321-32	6.6	57
37	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. <i>Journal of Virology</i> , <b>2016</b> , 90, 5899-5914	6.6	45
36	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. <i>Cell Host and Microbe</i> , <b>2019</b> , 26, 336-346.e3	23.4	43
35	A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. <i>Scientific Reports</i> , <b>2020</b> , 10, 18149	4.9	41
34	Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. <i>Lancet HIV,the</i> , <b>2019</b> , 6, e667-e679	7.8	33
33	Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody. <i>Cell Reports</i> , <b>2018</b> , 22, 1798-1809	10.6	33
32	Virological Control by the CD4-Binding Site Antibody N6 in Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	32
31	Accumulation of follicular CD8+ T cells in pathogenic SIV infection. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 2089-2103	15.9	31
30	Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 18754-18763	11.5	28
29	Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	27
28	Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. <i>Nature Communications</i> , <b>2020</b> , 11, 70	17.4	21
27	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabj5413	17.5	18

26	Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529.. <i>Science</i> , <b>2022</b> , 376, eabn8897	33.3	18
25	Improvement of antibody functionality by structure-guided paratope engraftment. <i>Nature Communications</i> , <b>2019</b> , 10, 721	17.4	17
24	Afferent and efferent interfaces of lymph nodes are distinguished by expression of lymphatic endothelial markers and chemokines. <i>Lymphatic Research and Biology</i> , <b>2007</b> , 5, 91-103	2.3	16
23	Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. <i>Human Vaccines and Immunotherapeutics</i> , <b>2018</b> , 14, 2116-2127	4.4	14
22	Glycoengineering HIV-1 Env creates supercharged and hybrid glycans to increase neutralizing antibody potency, breadth and saturation. <i>PLoS Pathogens</i> , <b>2018</b> , 14, e1007024	7.6	12
21	Bispecific antibodies: Potential immunotherapies for HIV treatment. <i>Methods</i> , <b>2019</b> , 154, 118-124	4.6	12
20	Delayed vaginal SHIV infection in VRC01 and anti- $\alpha\alpha$ treated rhesus macaques. <i>PLoS Pathogens</i> , <b>2019</b> , 15, e1007776	7.6	11
19	TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009339	7.6	11
18	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. <i>PLoS Pathogens</i> , <b>2019</b> , 15, e1007632	7.6	9
17	Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 3299-3304	15.9	9
16	Eliminating antibody polyreactivity through addition of N-linked glycosylation. <i>Protein Science</i> , <b>2015</b> , 24, 1019-30	6.3	8
15	Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants <b>2021</b> ,		6
14	Anti-HIV-1 Antibodies: An Update. <i>BioDrugs</i> , <b>2020</b> , 34, 121-132	7.9	5
13	Enhancing durability of CIS43 monoclonal antibody by Fc mutation or AAV delivery for malaria prevention. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	4
12	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.. <i>Cell Reports</i> , <b>2022</b> , 38, 110199	10.6	3
11	Removal of variable domain -linked glycosylation as a means to improve the homogeneity of HIV-1 broadly neutralizing antibodies. <i>MAbs</i> , <b>2020</b> , 12, 1836719	6.6	3
10	Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009738	7.6	3
9	Broadly neutralizing antibodies target the coronavirus fusion peptide. <b>2022</b> ,		3

8	A Platform Incorporating Trimeric Antigens into Self-Assembling Nanoparticles Reveals SARS-CoV-2-Spike Nanoparticles to Elicit Substantially Higher Neutralizing Responses than Spike Alone <b>2020</b> ,		2
7	Blocking $\alpha$ Integrin delays viral rebound in SHIV-infected macaques treated with anti-HIV broadly neutralizing antibodies. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	2
6	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. <b>2022</b> ,		1
5	Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base. <i>Cell Reports</i> , <b>2021</b> , 35, 108937	10.6	1
4	A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention. <i>MAbs</i> , <b>2021</b> , 13, 1946918	6.6	1
3	Convergent epitope specificities, V gene usage and public clones elicited by primary exposure to SARS-CoV-2 variants. <b>2022</b> ,		1
2	Anatomic Distribution of Intravenously Injected IgG Takes Approximately 1 Week to Achieve Stratum Corneum Saturation in Vaginal Tissues. <i>Journal of Immunology</i> , <b>2021</b> , 207, 505-511	5.3	0
1	B-108 Germinal center CD8 T cells can be redirected to eliminate HIV-expressing T follicular helper cells. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2014</b> , 67, 47	3.1	